Company profile
AngioDynamics, Inc.
NASDAQ: ANGO · Healthcare · Medical - Instruments & Supplies
#254 of 1,422 Healthcare companies by revenue36th-percentile growth
EA Score
——FH —DQ 84GM —SS 80
v0.1 · 25/100 weight · pillars only
↑ growth stability, disclosure history · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$313.7M
Rev growth YoY (TTM)
+10.7%
Net income (FY)
-$34.0M
Employees
632
as of 2026-08-11
Market cap
$651.0M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$292.5M$292.5M2025
Net income-$34.0M-$34.0M2025
Operating income-$40.0M-$40.0M2025
Total assets$280.1M$280.1M2025
Liabilities$97.2M$97.2M2025
Equity$183.0M$183.0M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY22
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is AngioDynamics, Inc.’s revenue?
AngioDynamics, Inc. booked $292.5M in FY2025 revenue, contracting 3.8% year over year — slower than 64% of Healthcare companies we track, at a -11.6% net margin.
Peers · Healthcare
Ironwood Pharmaceuticals, Inc.79B+Inogen, Inc.71BRigel Pharmaceuticals, Inc.81B+Xeris Biopharma Holdings, Inc.64CAurinia Pharmaceuticals Inc.78B+Adaptive Biotechnologies Corporation68BNeighbors
Albany →Key facts
CEOJames C. Clemmer
SectorHealthcare
IndustryMedical - Instruments & Supplies
HeadquartersLatham, NY
ExchangeNASDAQ: ANGO
Employees632
IPO date2004-06-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.